๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Randwick
Clinical trial register · Australia

Clinical Trials in Randwick, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Australia and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 3331 matching records held by the registry are in this view. Synced 26 Sep 2026, 19:46 UTC
3331
Studies in scope
all four open statuses
1807
Recruiting now
open to new participants
758
Lead sponsors
across recruiting studies
Top sites
Melbourne 1087 Adelaide 564 Sydney 508 Westmead 416 Clayton 409
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Children's Oncology Group15 AstraZeneca10 Nationwide Children's Hospital7 National Cancer Institute (NCI)7 Hoffmann-La Roche7
Site location
Melbourne1087 Adelaide564 Sydney508 Westmead416 Clayton409
All 397 locations
Target enrolment
to

Trials with a site in Randwick

208 of 3331 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Australia
Start
Recruiting
Pilot Study of ZetaFuseโ„ข Bone Graft for the Treatment of Cervical Degenerative Disc Disease
NCT05971329Radiculopathy, Cervical, Myelopathy Cervical, Neurological Abnormality, Disc Disease
Zetagen Therapeutics, Inc
Not applicable
10
Randwick
2026-09
Not yet open
VBC117First-in-Human Trial of VBC117 in Participants With Advanced Malignant Solid Tumors
NCT07772934Advanced Solid Tumors
VelaVigo Bio Inc
Phase 1/2
260
Randwick, Wollongong, Frankston
2026-08-24
Not yet open
A First-in-Human Study of ZE66-0205 in Healthy Volunteers
NCT07735728Healthy Volunteers (HV)
Eilean Therapeutics
Phase 1
32
Randwick
2026-08-15
Not yet open
To Evaluate the Safety, Tolerability, Pharmacokinetics and the Effect of Food on the Hemay5259 Sustained-release Tablets in Healthy Subjects.
NCT07703904Pharmacokinetics
Hemay Pharmaceutical PTY. LTD.
Phase 1
32
Randwick
2026-07-01
Recruiting
A Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)
NCT07286266Ovarian Neoplasms
DrugsMocertatug rezetecan·Pegylated liposomal doxorubicin·Topotecan·Gemcitabine
GlaxoSmithKline
Phase 3
450
Randwick
2026-06-18
Recruiting
DIAG723 in Adults With Hereditary Hemorrhagic Telangiectasia
NCT07623525Hereditary Hemorrhagic Telangiectasia, Pulmonary Arterial Hypertension
Diagonal Therapeutics, Inc.
Phase 1/2
93
Camperdown, Randwick, Herston, East Melbourne, Parkville, West Perth
2026-06-04
Recruiting
A Phase 1 Study of D3S-003 as Monotherapy in Participants With Advanced Solid Tumors With a KRAS p.G12D Mutation.
NCT07456046KRAS P.G12D
D3 Bio (Wuxi) Co., Ltd
Phase 1
42
Macquarie Park, Randwick, Malvern
2026-05-29
Recruiting
A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety When Given Before Symptoms Appear in Babies With Genetically Diagnosed Spinal Muscular Atrophy (SMA)
NCT07221669Muscular Atrophy, Spinal
DrugSalanersen
Biogen
Phase 3
30
Randwick
2026-04-28
Recruiting
A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression
NCT07546500Ovarian Cancer
DrugAzenosertib
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Phase 3
420
Randwick, Adelaide, Nedlands
2026-04-17
Recruiting
Safety and Tolerability of ZE74-0282 in Healthy Volunteers
NCT07527221Healthy Volunteers
Eilean Therapeutics AU Pty Ltd
Phase 1
64
Randwick
2026-04-16
Recruiting
DAREON ยฎ -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy
NCT07472517Small Cell Lung Cancer (SCLC), Extensive-stage Small Cell Lung Cancer (ES-SCLC)
DrugsObrixtamig·Etoposide·Atezolizumab·Carboplatin
Boehringer Ingelheim
Phase 3
670
Randwick, Adelaide, Ballarat
2026-04-13
Not yet open
Modulation of Stem Cell Differentiation in Individuals With High Risk Clonal Haematopoiesis
NCT07435636Clonal Cytopenia of Uncertain Significance, CCUS Clonal Cytopenia of Undetermined Significance, Clonal Hematopoiesis
Clinical Hub for Interventional Research (CHOIR)
Phase 2
80
Canberra, Randwick, Westmead
2026-04-13
Recruiting
Early-phase Trial to Assess the Safety and Preliminary Efficacy of BNT3214 in Adults With Advanced Solid Tumors
NCT07455734Advanced Solid Tumor Cancer
BioNTech SE
Phase 1/2
533
Clayton, Heidelberg Heights, Melbourne, Randwick, Richmond
2026-03-30
Recruiting
A Trial to Study if REGN17372 in Combination With Linvoseltamab is Tolerable for Adult Participants With Relapsed/Refractory Multiple Myeloma
NCT07455851Relapsed Refractory Multiple Myeloma (RRMM)
DrugLinvoseltamab
Regeneron Pharmaceuticals
Phase 1/2
150
Randwick, Wollongong, Adelaide, Fitzroy, Melbourne
2026-03-26
Recruiting
Study of TRX-100 Evaluating the Safety, Pharmacokinetics, and Food Effect in Healthy Volunteers
NCT07526506Healthy Volunteer
DrugTRX-100
Traws Pharma, Inc.
Phase 1
32
Randwick
2026-03-25
Recruiting
Study in Advanced Solid Tumor Patients
NCT07300943Advanced Solid Tumor
Callio Therapeutics
Phase 1/2
306
Randwick, South Brisbane, Box Hill, Heidelberg, Melbourne, Nedlands
2026-03-19
Recruiting
First-in-Human Study of ADCE-B05 in Patients With Advanced Solid Tumors
NCT07362888Solid Tumors (Phase 1)
Adcendo ApS
Phase 1
180
Randwick, Bedford Park, Clayton, Melbourne
2026-03-17
Recruiting
A Multicenter Randomized Controlled Trial to Treat Acute T Cell Mediated Rejection in Kidney and Kidney-Pancreas Transplant Recipients
NCT06474273Rejection; Transplant, Kidney, Rejection; Transplant, Pancreas
DrugsMethylprednisolone·Prednisone
University of Sydney
Phase 3
540
Lambton, Randwick, Westmead, South Brisbane, Woolloongabba, Adelaide, Clayton, Murdoch
2026-03-13
Recruiting
Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
NCT07491445Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma
DrugsCetuximab·Nab-paclitaxel·Gemcitabine
Revolution Medicines, Inc.
Phase 3
900
Randwick, Waratah, East Melbourne
2026-03-09
Recruiting
A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
NCT07284849CRC (Colorectal Cancer)
DrugsINCA33890·Folfox·Bevacizumab
Incyte Corporation
Phase 3
700
Port Macquarie, Randwick, Waratah, Westmead, Wollongong, Southport, Townsville, Woolloongabba
2026-03-05
Recruiting
A Clinical Trial to Evaluate NB-4746 in Participants With Amyotrophic Lateral Sclerosis.
NCT07369076Amyotrophic Lateral Sclerosis (ALS)
Nura Bio
Phase 1/2
80
Concord, Randwick, Brisbane, Bedford Park, Caulfield South, Nedlands
2026-03-04
Recruiting
Nectero EAST System Retreatment Study
NCT07505082AAA - Abdominal Aortic Aneurysm, Aorta Aneurysm, Dilation Aorta
Nectero Medical, Inc.
Not applicable
10
Randwick
2026-03-03
Recruiting
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
NCT07431281Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Cancer
DrugsSonesitatug Vedotin·Zolbetuximab·Rilvegostomig·Leucovorin
AstraZeneca
Phase 3
2,130
Darlinghurst, Garran, Heidelberg, Murdoch, Randwick, Westmead, Woolloongabba
2026-02-03
Recruiting
Study of BPI-572270 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
NCT07435038Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Advanced Solid Tumors
Betta Pharmaceuticals Co., Ltd.
Phase 1/2
120
Blacktown, Randwick, Sydney, Bedford Park, Heidelberg, Nedlands
2026-01-29
Recruiting
A Study of DB-1324 in Advanced/Metastatic Gastrointestinal Tumors
NCT07263594Gastrointestinal Cancer
DualityBio Inc.
Phase 1/2
127
Randwick, South Brisbane, Nedlands
2026-01-20
Recruiting
A Study of JNJ-95566692 in Participants With Non-Hodgkin Lymphoid Malignancies
NCT07308132Lymphoma, Non-Hodgkin
DrugsJNJ-87801493·Loncastuximab Tesirine·Polatuzumab Vedotin·Vincristine
Janssen Research & Development, LLC
Phase 1
340
Clayton, Melbourne, North Ryde, Randwick
2026-01-20
Recruiting
A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults
NCT07222137Diabetes Mellitus, Type 1
DrugBaricitinib
Eli Lilly and Company
Phase 3
150
Adelaide, Box Hill, Brisbane, Melbourne, Parkville, Perth, Randwick, Westmead
2026-01-12
Recruiting
A Rollover Study Evaluating Sotorasib With or Without Panitumumab in Participants With KRAS p.G12C Mutation
NCT07172919Advanced Solid Tumors
DrugsSotorasib·Panitumumab
Amgen
Phase 2
14
Randwick
2026-01-02
Recruiting
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
NCT07218380Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Neoplasm Metastasis
DrugsVepugratinib·Pembrolizumab
Eli Lilly and Company
Phase 3
450
Box Hill, Brisbane, Campbelltown, Heidelberg, Macquarie University, Perth, Randwick, St Albans
2025-12-12
Recruiting
A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014)
NCT07209111Neoplasm Malignant
DrugsCalderasib·Cetuximab
Merck Sharp & Dohme LLC
Phase 2
150
Randwick, Westmead, Melbourne
2025-12-04
Recruiting
Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-304 in Adults With Advanced HER2-Expressing Solid Tumors
NCT07334119HER2-Expressing Solid Tumors
DrugNivolumab
Myeloid Therapeutics
Phase 1
60
Darlinghurst, Randwick, Waratah, South Brisbane, Adelaide, Melbourne, Nedlands
2025-11-25
Recruiting
Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation
NCT07211958Acute Myeloid Leukemias
DrugRevumenib
Syndax Pharmaceuticals
Phase 3
468
Kingswood, Kogarah, Randwick, South Brisbane, Melbourne, Nedlands, Perth, Gosford
2025-11-25
Recruiting
A Study of ABT-301 Plus Tislelizumab With Bevacizumab in pMMR/Non-MSI-H Locally Advanced or mCRC
NCT07244705Colorectal Cancer (Diagnosis), Colorectal Cancer Metastatic, Colorectal Cancer (CRC), Immunotherapy
DrugsAvastin·Tislelizumab·Bevacizumab
Anbogen Therapeutics, Inc.
Phase 1/2
66
Liverpool, Macquarie Park, Randwick, Greenslopes, Woodville South, Clayton, Heidelberg, Nedlands
2025-11
Recruiting
PRophylaxis Against Early VENTilator-associated Infections in Acute Brain Injury
NCT06819592All-cause Mortality, Quality of Life, Disability, Intellectual, Neurological Disorder
The George Institute
Phase 3
3,300
Canberra, Camperdown, Darlinghurst, Dubbo, Kingswood, Kogarah, Liverpool, Randwick
2025-10-30
Recruiting
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
NCT07213804Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms, Neoplasm Metastasis
DrugsMIRV·Pegylated liposomal doxorubicin·Topotecan·Gemcitabine
Eli Lilly and Company
Phase 3
1,630
Ballarat Central, Camperdown, Launceston, Malvern, Randwick, Shepparton, Southport, St Leonards
2025-10-22
Recruiting
A Study of DB-1317 in Selected Advanced/Metastatic Solid Tumors
NCT07141706Advanced/Metastatic Solid Tumors
DualityBio Inc.
Phase 1
253
Liverpool, Randwick, Westmead, Nedlands
2025-09-23
Recruiting
A First-in-human, Dose Escalation and Indication Expansion Study of BNT3212 as Monotherapy or in Combination With BNT327 in Adults With Advanced Solid Tumors
NCT07147348Advanced Solid Tumor
DrugPumitamig
BioNTech SE
Phase 1/2
375
Adelaide, Clayton, Melbourne, Nedlands, Randwick
2025-08-27
Recruiting
FLudrocortisone Administration in Aneurysmal Subarachnoid Haemorrhage
NCT06409364Aneurysmal Subarachnoid Hemorrhage
DrugFludrocortisone
The George Institute
Phase 2
524
New Lambton Heights, Penrith, Randwick, St Leonards, Westmead, Wollongong, Brisbane, Gold Coast
2025-08-13
Recruiting
A Study to Test the Safety and Tolerability of SBO-154 in Patients With Advanced Solid Tumors.
NCT07042100Advanced Solid Tumors
DrugPumitamig
Sun Pharma Advanced Research Company Limited
Phase 1
177
Randwick, Birtinya, Adelaide
2025-08-12
Active, closed
Pivotal, Prospective, Multi-centre, Single-arm Study to Evaluate the Safety and Effectiveness of Oli for Identification of Patients, During the Intrapartum Period, Who Are at Higher Risk of Developing Abnormal Postpartum Uterine Bleeding, Including Postpartum Haemorrhage
NCT06655207Post Partum Haemorrhage, Maternal Care Patterns, High Risk Pregnancy
Baymatob Operations Pty Ltd
Not applicable
1,000
Randwick, St Leonards
2025-08-06
Recruiting
Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion
NCT06333899High Grade Glioma, Diffuse Intrinsic Pontine Glioma, Anaplastic Astrocytoma, Infant Type Hemispheric Glioma
DrugLorlatinib
Nationwide Children's Hospital
Phase EARLY_PHASE1
15
Randwick, South Brisbane, Perth
2025-08-03
Recruiting
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
NCT07044336Endometrial Cancer, Malignant Solid Tumour
DrugsAdriamycin·Taxol·Doxorubicin·Paclitaxel
AstraZeneca
Phase 3
800
Malvern, Melbourne, Randwick, St Leonards, Subiaco, Westmead
2025-08-01
Recruiting
HeartGPS: A Study Exploring the Effects of a Psychological Intervention for Parents and Their Babies After Prenatal Cardiac Diagnosis
NCT06175104Heart Defects, Congenital, Anxiety in Pregnancy, Depression, Postpartum, Trauma, Psychological
Children's Hospital Medical Center, Cincinnati
Not applicable
50
Randwick, Westmead
2025-07-14
Recruiting
ACT001 for the Treatment of Diffuse Intrinsic Pontine Gliomas and H3K27-altered High Grade Gliomas
NCT06838676Diffuse Intrinsic Pontine Gliomas (DIPG), Progressive DIPG, Refractory DIPG, Recurrent DIPG
DrugACT001
Nationwide Children's Hospital
Phase 2
60
Randwick, South Brisbane, Melbourne, Perth
2025-07-10
Recruiting
Steps Against the Burden of Parkinson's Disease
NCT07057219Parkinson Disease (PD)
The University of New South Wales
Not applicable
42
Randwick
2025-07-09
Recruiting
A Study to Investigate the Efficacy and Safety of Bemdaneprocel in Adults Who Have Parkinson's Disease
NCT06944522Parkinsons Disease (PD)
BlueRock Therapeutics
Phase 3
102
Randwick, Southport, Woolloongabba, Clayton, Melbourne, Parkville
2025-06-17
Recruiting
A Phase 2 Study of Mutant-selective PI3Kฮฑ Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation (The ReInspire Study)
NCT06789913PIK3CA-Related Overgrowth Spectrum (PROS), Lymphatic Malformations, Vascular Malformations, PIK3CA Mutation
DrugRLY-2608
Relay Therapeutics, Inc.
Phase 2
277
Randwick, South Brisbane, Clayton, Parkville
2025-06-13
Recruiting
REVEAL: A Phase 3 Study of Obudanersen (ION582) in Angelman Syndrome
NCT06914609Angelman Syndrome
DrugObudanersen
Ionis Pharmaceuticals, Inc.
Phase 3
158
South Brisbane, Heidelberg, Nedlands, Randwick
2025-06-10
Recruiting
A Study to Learn More About the Effects and Long-Term Safety of Omaveloxolone (BIIB141) in Children and Teens With Friedreich's Ataxia
NCT06953583Friedreich Ataxia
DrugsSkyclarys·Omaveloxolone
Biogen
Phase 3
255
Randwick, Parkville
2025-06-09
Recruiting
Digitally Delivered Treatments to Reduce Chronic Low Back Pain
NCT06984354Low Back Pain, Chronic Pain (Back / Neck), General Practice (GP), Primary Care Settings, Digital Health
Neuroscience Research Australia
Not applicable
720
Randwick
2025-06-02
Recruiting
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
NCT06921785Hepatocellular Carcinoma
DrugsRilvegostomig·Tremelimumab·Atezolizumab·Bevacizumab
AstraZeneca
Phase 3
1,220
Auchenflower, Camperdown, Clayton, Heidelberg, Randwick
2025-05-06
Recruiting
A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
NCT06846671CLL, Chronic Lymphocytic Leukemia
DrugsIdelalisib·Tacabrutideg·Bendamustine·Venetoclax
BeOne Medicines
Phase 3
250
Concord, Gosford, Port Macquarie, Randwick, Toowoomba, Bedford PK, Melbourne, West Perth
2025-04-10
Recruiting
Phase 1 Study to Evaluate the Safety and Tolerability of Intravenously Administered PYC-003
NCT06714006Autosomal Dominant Polycystic Kidney Disease (ADPKD)
PYC Therapeutics
Phase 1
166
Southport, Concord, Liverpool, Randwick, Wahroonga, Westmead, South Brisbane, Fitzroy
2025-04-07
Recruiting
SNV4818 in Participants With Advanced Solid Tumors
NCT06736704Advanced Solid Tumors
DrugsPalbociclib·Fulvestrant
Pikavation Therapeutics, Inc.
Phase 1/2
320
Camperdown, Randwick, Clayton, Melbourne, Nedlands
2025-02-20
Recruiting
A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease
NCT06612268Sickle Cell Disease
DrugEtavopivat
Novo Nordisk A/S
Phase 3
510
Camperdown, Randwick, Clayton, Murdoch
2025-02-17
Recruiting
A Study of DM002 in Patients With Advanced Solid Tumors
NCT06751329Ovarian Neoplasms, Prostatic Neoplasms, Endometrial Neoplasms, Colorectal Neoplasms
Xadcera Biopharmaceutical (Suzhou) Co., Ltd.
Phase 1/2
280
Randwick, Wollongong, Adelaide
2025-02-17
By invitation
A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathy (DEE)
NCT06908226Developmental and Epileptic Encephalopathy
DrugLP352
Longboard Pharmaceuticals
Phase 3
324
Randwick, Westmead, Brisbane, Heidelberg, Parkville
2025-02-12
Recruiting
A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)
NCT06858579Chronic Inflammatory Demyelinating Polyneuropathy
DrugClaseprubart
Dianthus Therapeutics
Phase 3
256
Liverpool, Randwick, Saint Leonards, Sydney, Southport, Melbourne
2025-02-10
Recruiting
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK202 in Participants with Advanced Solid Tumors
NCT06707610Advanced Cancer, Advanced Solid Tumor
Shanghai Allink Biotherapeutics Co., Ltd.
Phase 1
234
Randwick, Sydney
2025-02-10
Recruiting
Study of Olutasidenib and Temozolomide in HGG
NCT06161974High Grade Glioma, Astrocytoma, Astrocytoma, Grade III, Astrocytoma, Grade IV
DrugOlutasidenib
Rigel Pharmaceuticals
Phase 2
60
Randwick, South Brisbane, Perth
2025-02-01
Recruiting
Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid Tumors
NCT06750185Advanced Solid Tumor
BioNTech SE
Phase 1/2
248
Southport, Adelaide, Clayton, Randwick
2025-01-13
By invitation
A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring
NCT06788509Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes
DrugsJNJ-75348780·JNJ-87801493·JNJ-80948543·Ibrutinib
Janssen Research & Development, LLC
Phase 1
120
Macquarie University, Melbourne, Nedlands, Randwick
2024-12-30
Active, closed
A Study to Test Long-term Treatment With Brigimadlin in People With Solid Tumours Who Took Part in a Previous Study With This Medicine
NCT06619509Solid Tumours
Boehringer Ingelheim
Phase 2
90
Randwick, Woolloongabba
2024-12-30
Recruiting
BMB-101 in Absence Epilepsy and DEE
NCT06401538Absence Epilepsy, Jeavons Syndrome, Dravet Syndrome, Lennox Gastaut Syndrome
DrugBMB-101
Bright Minds Biosciences Pty Ltd
Phase 2
20
Randwick, Herston, Fitzroy, Heidelberg, Melbourne
2024-12-05
Recruiting
ADCE-T02, a Tissue Factor Targeted Antibody-Drug Conjugate, in Patients With Selected Advanced Solid Tumours
NCT06597721Advanced Solid Tumor, PDAC, HNSCC
Adcendo ApS
Phase 1
210
Macquarie Park, Randwick, Bedford Park, Frankston, Malvern, Melbourne, Nedlands
2024-11-25
Recruiting
A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
NCT06647498Alzheimers Disease, Dementia, Alzheimers Disease, Familial
DrugRemternetug
Washington University School of Medicine
Phase 2/3
280
Randwick, Melbourne
2024-11-22
Recruiting
A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
NCT05552157Alzheimers Disease, Dementia, Alzheimers Disease, Familial
DrugRemternetug
Washington University School of Medicine
Phase 2/3
280
Randwick, Melbourne
2024-11-22
Recruiting
LaCE (Lactobacillus Paracasei LPB27 On Early Childhood Eczema)
NCT06584552Eczema, Allergy
The University of New South Wales
Phase 2
100
Randwick
2024-11-15
Active, closed
A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathies (DEE)
NCT06719141Developmental and Epileptic Encephalopathy
DrugLP352
Longboard Pharmaceuticals
Phase 3
367
Randwick, Westmead, Brisbane, Heidelberg, Melbourne, Parkville
2024-11-11
Recruiting
An Open Label Dose Finding Study of PTT-4256 in Patients With Solid Tumours (RAISIC-1).
NCT06634849Advanced Solid Tumor
Pathios Therapeutics Pty Ltd
Phase 1/2
30
Blacktown, Randwick, Adelaide, Heidelberg, Nedlands
2024-11-04
Recruiting
Study of Intralesional FLD-103 in Subjects With Basal Cell Carcinoma (BCC)
NCT07670858Nodular Basal Cell Carcinoma
Feldan Therapeutics
Phase 1
48
Phillip, Charlestown, Randwick, Waitara, Westcourt, Woolloongabba
2024-10-30
Recruiting
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
NCT06625775Solid Tumor, Adult, Metastatic Breast Cancer, Advanced Breast Cancer, HER2 Mutation-Related Tumors
DrugsBBO-10203·Ribociclib·Folfox·Fulvestrant
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Phase 1
392
Randwick, Melbourne
2024-10-29
Recruiting
A Study of Lower Radiotherapy Dose to Treat Children With CNS Germinoma
NCT06368817Basal Ganglia Germinoma, Diabetes Insipidus, Germinoma, Pineal Region Germinoma
DrugsEtoposide·Carboplatin
Children's Oncology Group
Phase 2
240
Hunter Regional Mail Centre, Randwick, Westmead, South Brisbane, North Adelaide, Parkville, Perth
2024-10-22
Active, closed
A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS)
NCT06660394Dravet Syndrome
DrugLP352
Longboard Pharmaceuticals
Phase 3
96
Randwick, Westmead, Brisbane, Heidelberg, Melbourne, Parkville
2024-09-25
Recruiting
Prospective Study Evaluating the Treatment Outcomes for Localised Recurrent, Resectable Retroperitoneal Liposarcoma
NCT07377747Retroperitoneal Liposarcoma
Australia and New Zealand Sarcoma Association
Observational
100
Camperdown, Randwick, Melbourne
2024-09-05
Recruiting
First-in-human Study of DB-1419 for Advanced/Metastatic Solid Tumors
NCT06554795Solid Tumor, Adult
DualityBio Inc.
Phase 1/2
360
North Ryde, Randwick, Nedlands
2024-09-03
Recruiting
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
NCT05843253High Grade Glioma, Diffuse Intrinsic Pontine Glioma, Anaplastic Astrocytoma, Glioblastoma
DrugsEverolimus·Ribociclib·Temozolomide
Nationwide Children's Hospital
Phase 2
120
Randwick, South Brisbane, Melbourne, Perth
2024-08-22
Active, closed
A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors
NCT06533059Cancer, Breast Cancer, Endometrial Cancer, Metastatic Cancer
Alterome Therapeutics, Inc.
Phase 1
110
Randwick, Malvern, Nedlands
2024-08-22
Recruiting
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
NCT06395103B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma, Burkitt Lymphoma, Neuroblastoma
DrugZilovertamab vedotin
Merck Sharp & Dohme LLC
Phase 1/2
90
Randwick, Brisbane, Melbourne
2024-08-16
Recruiting
Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease
NCT06332534Crohn's Disease
DrugUpadacitinib
AbbVie
Phase 3
110
Randwick, Westmead, South Brisbane, Clayton, Perth
2024-08-08
Recruiting
Targeted Pediatric High-Grade Glioma Therapy
NCT05839379High Grade Glioma, Diffuse Intrinsic Pontine Glioma, Anaplastic Astrocytoma, Glioblastoma
Nationwide Children's Hospital
Observational
350
Randwick, South Brisbane, Melbourne, Perth
2024-08-02
By invitation
Long-term Safety and Tolerability of BHV-7000
NCT06443463Focal Epilepsy
DrugOpakalim
Biohaven Therapeutics Ltd.
Phase 2
660
Camperdown, Randwick, Herston, Fitzroy, Heidelberg, Melbourne, Parkville, Bedford Park
2024-07-30
Recruiting
Immunotherapy Targeting of Cytomegalovirus Antigens in Glioblastoma
NCT06132438Glioblastoma
Charlotte Lemech
Phase 1
26
Liverpool, Randwick
2024-07-22
Recruiting
A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myasthenia Gravis
NCT06392386Generalized Myasthenia Gravis
DrugEfgartigimod PH20
argenx
Phase 2/3
12
Melbourne, Randwick
2024-06-28
Active, closed
ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack
NCT06118281Cardiovascular Risk, Acute Myocardial Infarction (AMI)
DrugZiltivekimab
Novo Nordisk A/S
Phase 3
10,000
Concord, Kingswood, Liverpool, Randwick, Wollongong, Birtinya, Brisbane, Cairns
2024-06-25
Recruiting
AMT-676 in Patients With Advanced Solid Tumors
NCT06400485Advanced Solid Tumors
DrugAMT-676
Multitude Therapeutics Inc.
Phase EARLY_PHASE1
24
Randwick, Macquarie, Greenslopes, Melbourne, Nedlands
2024-06-18
Active, closed
DIAN-TU Amyloid Removal Trial (ART) in Dominantly Inherited Alzheimer's Disease
NCT06384573Alzheimer's Disease, Dementia, Alzheimer's Disease, Familial
DrugLecanemab
Washington University School of Medicine
Phase 3
40
Randwick
2024-06-10
Recruiting
Comparative Effectiveness Study of Two Forms of Ketamine for Treatment-resistant Depression
NCT06278779Treatment Resistant Depression
The George Institute
Phase 4
162
Camperdown, Randwick, St Leonards, Warners Bay, Southport, Melbourne, Parkville
2024-06-03
Recruiting
A Study of Pitolisant in Patients With Prader-Willi Syndrome
NCT06366464Prader-Willi Syndrome
DrugPitolisant
Harmony Biosciences Management, Inc.
Phase 3
134
Brisbane, Camperdown, Randwick, Westmead
2024-05-28
Active, closed
Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy
NCT06309966Focal Epilepsy
DrugOpakalim
Biohaven Therapeutics Ltd.
Phase 2/3
390
Camperdown, Randwick, Herston, Fitzroy, Heidelberg, Melbourne, Parkville, Bedford Park
2024-05-13
Recruiting
The Natural History of Mitochondrial Diseases
NCT06504433Mitochondrial Diseases, Neurological Diseases or Conditions, Genetic Disease
Neuroscience Research Australia
Observational
500
Randwick
2024-05-07
Active, closed
S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAP
NCT06188702MTAP-deleted Solid Tumors
DrugTNG462
Servier Bio-Innovation LLC
Phase 1/2
60
Randwick, Prahran, Douglas, Hobart
2024-04-29
Recruiting
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
NCT06172296Ganglioneuroblastoma, Nodular, Neuroblastoma
DrugsDinutuximab·Isotretinoin·CDDP·Doxorubicin
National Cancer Institute (NCI)
Phase 3
478
Randwick, Westmead, South Brisbane, Parkville, Perth
2024-04-19
Recruiting
A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
NCT06326411Oncology, MEK Mutation, RAF Gene Mutation, Ras (KRAS or NRAS) Gene Mutation
Nested Therapeutics, Inc
Phase 1
230
Darlinghurst, Randwick, Greenslopes, Adelaide, Malvern
2024-04-09
Active, closed
An International, Multicenter, Randomized, Double-Blind, Parallel Group, Vehicle-Controlled, Phase 2/3 Study With Open-Label Extension Evaluating the Efficacy and Safety of Diacerein 1% Ointment for the Treatment of Generalized Epidermolysis Bullosa Simplex (EBS)
NCT06073132Generalized Epidermolysis Bullosa Simplex
TWi Biotechnology, Inc.
Phase 2/3
80
Kogarah, Randwick
2024-04-04
Recruiting
A Study With Tovorafenib (DAY101) as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell Histiocytosis
NCT05828069Recurrent Langerhans Cell Histiocytosis, Refractory Langerhans Cell Histiocytosis
DrugTovorafenib
National Cancer Institute (NCI)
Phase 2
48
Randwick, South Brisbane, Parkville, Perth
2024-03-28
Recruiting
A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer
NCT06072781Low Grade Serous Ovarian Cancer
DrugsDefactinib·Avutometinib·Pegylated liposomal doxorubicin·Anastrozole
Verastem, Inc.
Phase 3
270
Randwick, Auchenflower, Adelaide, Melbourne, Nedlands
2024-03-18
Recruiting
Evaluation of the MAGNITUDEยฎ Bioresorbable Drug-Eluting Scaffold in the Treatment of Patients With Below the Knee Disease in Australia
NCT06075940Critical Limb-Threatening Ischemia, Critical Limb Ischemia, Critical Lower Limb Ischemia
R3 Vascular Inc.
Not applicable
30
Randwick
2024-03-04
Recruiting
SNV1521 in Participants With Advanced Solid Tumors
NCT06220864Advanced Solid Tumor
DrugsDB-1310·Abiraterone·Darolutamide
Synnovation Therapeutics, Inc.
Phase 1
400
Randwick, Woolloongabba, Clayton, Melbourne, Crawley
2024-02-23
Active, closed
Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment
NCT06151574Lung Cancer, Non-squamous, Non-small Cell
DrugsZongertinib·Pemetrexed·Keytruda·Cisplatin
Boehringer Ingelheim
Phase 3
428
Randwick, St Leonards, Woolloongabba, Heidelberg, Subiaco
2024-02-09
Rows per page Showing 1–100 of 208
1 2 3 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with an Australian investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 28 September 2026. https://priyalifescience.com/clinical-trials-australia/city/randwick

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Australia and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 3,331 studies in total at the last sync on 26 Sep 2026, 19:46 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 208 of those studies with a site in Randwick.

How many clinical trials are recruiting in Randwick?

132 of the 208 studies on this page are recruiting new participants as of the 26 Sep 2026, 19:46 UTC sync. A further 4 have not yet opened recruitment, 67 are active but closed to new participants, and 5 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Randwick), 208 studies
PhaseStudiesRecruitingShare
Phase 3683532.7%
Phase 2372317.8%
Phase 1/2362817.3%
Phase 1302014.4%
Not applicable16117.7%
Phase 2/31265.8%
Observational552.4%
Phase EARLY_PHASE1331.4%
Phase 4110.5%

Most active sponsors

Lead sponsors with the most studies (Randwick)
Lead sponsorStudiesRecruiting
Children's Oncology Group158
AstraZeneca106
Hoffmann-La Roche71
National Cancer Institute (NCI)74
Nationwide Children's Hospital77
Eli Lilly and Company63
Washington University School of Medicine52
BioNTech SE44
DualityBio Inc.44
Janssen Research & Development, LLC41
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.